Subcommittee members held a hearing title “Sick Crime: Counterfeit Drugs in the United States.” FDA officials, drug industry… read more
Subcommittee members held a hearing title “Sick Crime: Counterfeit Drugs in the United States.” FDA officials, drug industry representatives, and family members of counterfeit drug victims testified how counterfeit drugs enter the legitimate pharmaceutical market. Among the topics members of the panels spoke about were government regulation of the drug supply line, paper pedigrees, and criminal invesigations.
During the first panel, Commissioner Lutter spoke about implementations of stringent license requirements on the state level. He discussed the use of electronic devices and new technologies in the distribution of pharmaceuticals. The second panel talked about Carlos Luis, who bought Epogen and Procrit from a gentleman’s club in Miami. He moved the drugs into the wholesale market and the family of Tim Fagan sued a CVS subdiary for distributing Epogen, an anemia drug, after his emergency liver transplant. The third panel spoke about the growth of counterfeit drugs, accreditation of interstate wholesale distribution in states including Indiana, and suggestions to improve capture of criminal distributors.
Randall Lutter used charts and graphs during the opening panel. Representative Gutknecht displayed a “scare-ad” regarding drugs purchased in Canada. He also presented a digital chip that could be placed inside medications to identify the ingredients and only costs ten cents.
Katherine Eban is the author of Dangerous Doses: How Counterfeiters are Contaminating America’s Drug Supply, published by Harcourt. Mr. Fagan and Mr. Butler are relatives on counterfeit drug victims in Florida. close
*The transcript for this program was compiled from uncorrected Closed Captioning.
People in this video
- Carmen Catizone Executive Director National Association of Boards of Pharmacies
- Elijah Cummings U.S. Representative [D] Maryland
- Jim Dahl Assistant Director (Former) U.S. Food and Drug Administration->Office of Criminal Investigations
- Donald DeKieffer Attorney International Trade
- Katherine Eban Correspondent
- Kevin Fagan Father
- Gil Gutknecht U.S. Representative [R] Minnesota
- Steve Israel U.S. Representative [D] New York
- Randall Lutter Associate Commissioner (Acting) U.S. Food and Drug Administration->Policy and Planning
- Eleanor Holmes Norton Congressional Delegate [D] District of Columbia
- Peter Pitts Board Member Center for Medicines in the Public Interest
- Jean Marie Schmidt U.S. Representative [R] Ohio
- Mark Edward Souder U.S. Representative [R] Indiana
- Diane Watson U.S. Representative [D] California
RU-486 Health and Safety Standards
Witnesses testified about the safety record of the abortion-inducing drug RU-486 and standards for women’s health…
Synthetic Drug Control Strategy
The committee held a hearing to evaluate the administration’s first Synthetic Drug Control Strategy, which was…
Prescription Drug Abuse
Witnesses testified about prescription drug abuse, access to prescription drugs through physicians, the Internet, and…
Pharmaceutical Internet Sales
The House Energy and Commerce Subcommittee on Oversight and Investigations held a hearing titled “Safety of…